Related Experiment Video
Updated: Apr 14, 2026

Roux-en-Y Gastric Bypass Operation in Rats
Published on: June 11, 2012
Drug disposition and modelling before and after gastric bypass: immediate and controlled-release metoprolol
Ina Gesquiere1, Adam S Darwich2, Bart Van der Schueren3
1Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Aims:
The aim of the present study was to evaluate the disposition of metoprolol after oral administration of an immediate and controlled-release formulation before and after Roux-en-Y gastric bypass (RYGB) surgery in the same individuals and to validate a physiologically based pharmacokinetic (PBPK) model for predicting oral bioavailability following RYGB.
Methods:
A single-dose pharmacokinetic study of metoprolol tartrate 200 mg immediate release and controlled release was performed in 14 volunteers before and 6-8 months after RYGB. The observed data were compared with predicted results from the PBPK modelling and simulation of metoprolol tartrate immediate and controlled-release formulation before and after RYGB.
Results:
After administration of metoprolol immediate and controlled release, no statistically significant difference in the observed area under the curve (AUC(0-24 h)) was shown, although a tendency towards an increased oral exposure could be observed as the AUC(0-24 h) was 32.4% [95% confidence interval (CI) 1.36, 63.5] and 55.9% (95% CI 5.73, 106) higher following RYGB for the immediate and controlled-release formulation, respectively. This could be explained by surgery-related weight loss and a reduced presystemic biotransformation in the proximal gastrointestinal tract. The PBPK values predicted by modelling and simulation were similar to the observed data, confirming its validity.
Conclusions:
The disposition of metoprolol from an immediate-release and a controlled-release formulation was not significantly altered after RYGB; there was a tendency to an increase, which was also predicted by PBPK modelling and simulation.
Related Concept Videos
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
One-Compartment Open Model for IV Bolus Administration: General Considerations
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model

